SLC5A2 and chronic kidney disease: Hence, they are recommended as first-line therapy independently of background glucose-lowering agents, current human glycated hemoglobin (HbA1c) level or HbA1c targeted level in patients with T2DM and established or subclinical atherosclerotic cardiovascular disease (ASCVD) or CKD with the caveat that, in the latter, SGLT2 inhibitors ought to be preferred [6].